Document Detail


Delayed treatment effects of xanthine oxidase inhibition on systolic overload-induced left ventricular hypertrophy and dysfunction.
MedLine Citation:
PMID:  20544512     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The nonpurine selective xanthine oxidase (XO) inhibitor febuxostat attenuates development of left ventricular (LV) hypertrophy and dysfunction in mice when treatment is initiated within 1 hour of transverse aortic constriction (TAC). This study investigated whether a 7-day delay of treatment with the XO inhibitors febuxostat or allopurinol would reverse TAC-induced changes after onset of heart failure (HF). Neither treatment significantly affected TAC-induced LV hypertrophy; only febuxostat caused a modest improvement in LV function ( approximately 10% increase in LV ejection fraction). However, the purine analog allopurinol tended to increase mortality compared with vehicle or febuxostat in HF mice.
Authors:
X Xu; L Zhao; X Hu; P Zhang; J Wessale; R Bache; Y Chen
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Nucleosides, nucleotides & nucleic acids     Volume:  29     ISSN:  1532-2335     ISO Abbreviation:  Nucleosides Nucleotides Nucleic Acids     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-06-14     Completed Date:  2010-09-13     Revised Date:  2014-09-14    
Medline Journal Info:
Nlm Unique ID:  100892832     Medline TA:  Nucleosides Nucleotides Nucleic Acids     Country:  England    
Other Details:
Languages:  eng     Pagination:  306-13     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Allopurinol / therapeutic use*
Animals
Constriction, Pathologic / complications
Enzyme Inhibitors / therapeutic use*
Hypertrophy, Left Ventricular / drug therapy*,  etiology,  mortality
Male
Mice
Mice, Inbred C57BL
Thiazoles / therapeutic use*
Xanthine Oxidase / antagonists & inhibitors*
Grant Support
ID/Acronym/Agency:
R21 HL098669/HL/NHLBI NIH HHS; R21 HL098669-01A1/HL/NHLBI NIH HHS; R21 HL098669-02/HL/NHLBI NIH HHS; R21 HL102597/HL/NHLBI NIH HHS; R21 HL102597-01/HL/NHLBI NIH HHS; R21 HL102597-02/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Enzyme Inhibitors; 0/Thiazoles; 144060-53-7/febuxostat; 63CZ7GJN5I/Allopurinol; EC 1.17.3.2/Xanthine Oxidase
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Methylation status of HPRT1 promoter in HPRT deficiency with normal coding region.
Next Document:  Establishment and Analysis of SLC22A12 (URAT1) Knockout Mouse.